Impact of Pharmacist Intervention on Electrocardiogram Monitoring of Pediatric Patients on Multiple QTc Interval-Prolonging Medications.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Journal of Pediatric Pharmacology and Therapeutics

• Publication date

  2017-12-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.5863/1551-6776-22.6.399PMID 29290739PMCID PMC5736251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug-Induced QT Interval Prolongation in Children: Are the Kids Alright?

  2016cited by this paper
• Drug-induced QT interval prolongation and torsades de pointes

  2016cited by this paper
• Domperidone-Associated QT Interval Prolongation in Non-oncologic Pediatric Patients: A Review of the Literature.

  2016cited by this paper
• Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron

  2016cited by this paper
• Effectiveness of a Clinical Decision Support System for Reducing the Risk of QT Interval Prolongation in Hospitalized Patients

  2014cited by this paper
• Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.

  2014cited by this paper
• Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

  2010cited by this paper
• Clinically relevant QTc prolongation due to overridden drug-drug interaction alerts: a retrospective cohort study.

  2009cited by this paper
• Prevalence of the Congenital Long-QT Syndrome

  2009cited by this paper
• Pharmacist Monitoring of QTc Interval–Prolonging Medications in Critically Ill Medical Patients: A Pilot Study

  2008cited by this paper
• Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance database

  2008cited by this paper
• International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.

  2005cited by this paper
• Minimizing the risk for QT interval prolongation.

  2005cited by this paper
• The relevance of prolonged QTc measurement to pediatric psychopharmacology.

  2003cited by this paper
• Improving Recognition of Drug Interactions: Benefits and Barriers to Using Automated Drug Alerts

  2002cited by this paper
• New normal limits for the paediatric electrocardiogram.

  2001cited by this paper
• Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

  2001cited by this paper
• Proarrhythmia associated with cisapride in children.

  1998cited by this paper
• The Arrhythmias

  1958cited by this paper

• Pharmacist-assisted implementation of guideline recommendations for QTc monitoring during psychopharmacotherapy - a prospective, randomized feasibility study

  2025influential citation
• State-of-the-art wearable sensors for cardiovascular health: a review

  2025cites this paper
• Pharmacist Reported Protocols for QTc Monitoring of Psychiatric Medications.

  2024cites this paper
• Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID‐19

  2021cites this paper
• Evidence demonstrating the pharmacist's direct impact on clinical outcomes in pediatric patients: An opinion of the pediatrics practice and research network of the American College of Clinical Pharmacy

  2020cites this paper
• Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?

  2018cites this paper